GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in GeneDx and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) on behalf of GeneDx stockholders. Our investigation concerns whether GeneDx has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 5, 2025, Grizzly Research ("Grizzly") published a report entitled "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud". The Grizzly report asserted, among other things, that GeneDx's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue"; that "[t]estimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as ‘code stacking'", which "enables the company to bill insurance providers for services that do not meet the required criteria"; and that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases", a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company." On this news, GeneDx's stock price fell $4.84 per share, or 6.72%, to close at $67.18 per share on February 5, 2025. If you purchased or otherwise acquired GeneDx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

FAQ

Why Very Bearish?

How important is it?

Why Short Term?

Related Companies

Related News